<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="53273335-50e1-4587-bff4-0565a61f123b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DESCOVY safely and effectively. See full prescribing information for DESCOVY. <br/>
      <br/>DESCOVY<sup>®</sup> (emtricitabine and tenofovir alafenamide) tablets, for oral use <br/>Initial U.S. Approval: 2015</title>
   <effectiveTime value="20160408"/>
   <setId root="06f66e98-e6ee-4538-9506-6c1282cc14c1"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="185049848" root="1.3.6.1.4.1.519.1"/>
            <name>Gilead Sciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="bd1a0ce6-dffd-4d3d-8470-88aad88d9df0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20160412"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61958-2002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DESCOVY</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>emtricitabine and tenofovir alafenamide fumarate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G70B4ETF4S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>emtricitabine</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="G70B4ETF4S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>emtricitabine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="FWF6Q91TZO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tenofovir alafenamide fumarate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W4HFE001U5" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tenofovir anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="EL9943AG5J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tenofovir alafenamide</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61958-2002-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160404"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208215" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160404"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>rectangular-shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GSI;255</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="014535b7-450d-4575-9780-6ec350ad2304"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs in combination with other antiretrovirals <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DESCOVY is not approved for the treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy of DESCOVY have not been established in patients coinfected with human immunodeficiency virus-1 (HIV-1) and HBV. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of DESCOVY.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DESCOVY. If appropriate, initiation of anti-hepatitis B therapy may be warranted <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs. (<linkHtml href="#S5.1">5.1</linkHtml>) </content>
                           </item>
                           <item>
                              <content styleCode="bold">DESCOVY is not approved for the treatment of chronic hepatitis B virus (HBV) infection. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of DESCOVY. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted. (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="2e0980d4-9791-4d25-a5cb-84566cd2f8c4"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>DESCOVY is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>DESCOVY is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="6b86b7f3-3182-4e59-965a-ed4f3fb5de23"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>DESCOVY is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="8857d448-28ca-48f8-9019-ada847c86c88"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Testing: Prior to initiation of DESCOVY, patients should be tested for hepatitis B virus infection, and estimated creatinine clearance, urine glucose and urine protein should be obtained. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item> Recommended dosage: One tablet taken once daily with or without food in patients 12 years old and older with body weight at least 35 kg and a creatinine clearance greater than or equal to 30 mL per minute. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Renal impairment: DESCOVY is not recommended in patients with estimated creatinine clearance below 30 mL per minute. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="e62d03a4-a9fa-4536-bc3c-94d739c7a23f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Testing Prior to Initiation of DESCOVY</title>
                     <text>
                        <paragraph>Prior to initiation of DESCOVY, patients should be tested for hepatitis B virus infection <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Estimated creatinine clearance, urine glucose, and urine protein should be assessed before initiating DESCOVY therapy and should be monitored during therapy in all patients <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="5fbfe44f-93ae-4523-a597-76b160557b2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 	Recommended Dosage</title>
                     <text>
                        <paragraph>DESCOVY is a two-drug fixed dose combination product containing 200 mg of emtricitabine (FTC) and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of DESCOVY is one tablet taken orally once daily with or without food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance greater than or equal to 30 mL per minute  <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>For specific dosing recommendations for coadministered third agents, refer to their respective prescribing information<content styleCode="italics"> [see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="1973e518-e6c1-47f6-9d9a-39426bc747bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3       Not Recommended in Patients with Severe Renal Impairment</title>
                     <text>
                        <paragraph>DESCOVY is not recommended in patients with estimated creatinine clearance below 30 mL per minute <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="0705a947-0b3b-4cb4-bbe9-acdce2c25e59"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Each DESCOVY tablet contains 200 mg of emtricitabine (FTC) and 25 mg of tenofovir alafenamide (TAF) (equivalent to 28 mg of tenofovir alafenamide fumarate). The tablets are blue, rectangular-shaped, film-coated, debossed with "GSI" on one side and "225" on the other side.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 200 mg of FTC and 25 mg of TAF (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="f8891e84-149d-4a34-9cf1-93b9ee9f53ae"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="e0eacb5f-1a80-4ba5-a0a7-c45ab717d5ef"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item> Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item> Immune reconstitution syndrome: May necessitate further evaluation and treatment. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item> New onset or worsening renal impairment: Assess creatinine clearance, urine glucose, and urine protein in all patients before initiating DESCOVY therapy and monitor during therapy. Monitor serum phosphorus in patients with chronic kidney disease. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item> Bone loss and mineralization defects: Consider monitoring BMD in patients with a history of pathologic fracture or other risk factors of osteoporosis or bone loss. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="f7a9c54c-602f-4a8f-a0d2-ae1811c2f26d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1       Lactic Acidosis/Severe Hepatomegaly with Steatosis</title>
                     <text>
                        <paragraph>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs in combination with other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Since TAF and FTC are nucleos(t)ide analogs, treatment with DESCOVY should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="ce5cf185-73de-4c8f-b429-fa102d2cf18b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2       Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV</title>
                     <text>
                        <paragraph>Patients with HIV-1 should be tested for the presence of chronic hepatitis B virus (HBV) before initiating antiretroviral therapy<content styleCode="italics"> [see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>. DESCOVY is not approved for the treatment of chronic HBV infection, and the safety and efficacy of DESCOVY have not been established in patients coinfected with HIV-1 and HBV.</paragraph>
                        <paragraph>Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing FTC and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of DESCOVY. Patients coinfected with HIV-1 and HBV who discontinue DESCOVY should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, initiation of anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="a16b9c54-c985-40b9-8c87-f79d555d58a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3       Fat Redistribution</title>
                     <text>
                        <paragraph>Redistribution or accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="fba5c467-3d3b-43bc-9a14-021327234547"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4       Immune Reconstitution Syndrome</title>
                     <text>
                        <paragraph>Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including FTC, a component of DESCOVY. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as <content styleCode="italics">Mycobacterium avium</content> infection, cytomegalovirus, <content styleCode="italics">Pneumocystis jirovecii</content> pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.</paragraph>
                        <paragraph>Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="dea94509-ec3b-42dc-94ae-d366ab297874"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5       New Onset or Worsening Renal Impairment</title>
                     <text>
                        <paragraph>Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir prodrugs in both animal toxicology studies and human trials. In clinical trials of FTC+TAF with cobicistat (COBI) plus elvitegravir (EVG), there have been no cases of Fanconi syndrome or Proximal Renal Tubulopathy (PRT). In clinical trials of FTC+TAF with EVG+COBI in treatment-naïve subjects and in virally suppressed subjects switched to FTC+TAF with EVG+COBI with eGFRs greater than 50 mL per minute, renal serious adverse events or discontinuations due to renal adverse reactions were encountered in less than 1% of participants treated with FTC+TAF with EVG+COBI. In a study of virally suppressed subjects with baseline eGFRs between 30 and 69 mL per minute treated with FTC+TAF with EVG+COBI for a median duration of 43 weeks, FTC+TAF with EVG+COBI was permanently discontinued due to worsening renal function in two of 80 (3%) subjects with a baseline eGFR between 30 and 50 mL per minute <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. DESCOVY is not recommended in patients with estimated creatinine clearance below 30 mL per minute because data in this population are insufficient.</paragraph>
                        <paragraph>Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions.</paragraph>
                        <paragraph>Estimated creatinine clearance, urine glucose, and urine protein should be assessed before initiating DESCOVY therapy and should be monitored during therapy in all patients. Serum phosphorus should be monitored in patients with chronic kidney disease because these patients are at greater risk of developing Fanconi syndrome on tenofovir prodrugs. Discontinue DESCOVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="8c296d65-e5e0-4a03-adbf-5bac112cd0d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6       Bone Loss and Mineralization Defects</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="430f85bd-40a1-4485-904c-8d3befbb028e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Decrease in Bone Mineral Density (BMD):</content>
                              </paragraph>
                              <paragraph>In animal toxicology studies and human clinical trials, TAF and tenofovir have been associated with decreases in BMD and increases in biochemical markers of bone metabolism suggestive of increased bone turnover. In clinical trials in HIV-1 infected treatment-naïve adults, a significant decline in BMD was observed in 15% of subjects treated with FTC+TAF with EVG+COBI <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. The long-term clinical significance of these changes has not been established.</paragraph>
                              <paragraph>Assessment of BMD should be considered for adults and pediatric patients treated with DESCOVY who have a history of pathologic bone fracture or other risk factors for osteoporosis or bone loss. Calcium and vitamin D supplementation may be beneficial for all patients. If bone abnormalities are suspected, then appropriate consultation should be obtained.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c47f7ad6-0948-4daf-91a1-dcd9742a002b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mineralization Defects:</content>
                              </paragraph>
                              <paragraph>Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of TDF-containing products. Hypophosphatemia and osteomalacia secondary to PRT have occurred in patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms while receiving products containing TDF <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>. While not observed in clinical studies of DESCOVY, the risk of osteomalacia with DESCOVY is not known.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="593fd784-b586-4055-aa9d-2fd14b51cfd7"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Lactic Acidosis/Severe Hepatomegaly with Steatosis<content styleCode="italics"> [see <linkHtml href="#BOX">Boxed Warning</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Severe Acute Exacerbations of Hepatitis B <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                     <item>Immune Reconstitution Syndrome <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</item>
                     <item>New Onset or Worsening Renal Impairment<content styleCode="italics"> [see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</item>
                     <item>Bone Loss and Mineralization Defects <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reaction (incidence greater than or equal to 10%, all grades) is nausea. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="30474488-4962-495a-b058-061dbf440d1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug (or a drug given in various combinations with other concomitant therapy) cannot be directly compared to rates in the clinical trials of another drug (or drug given in the same or different combination therapy) and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="78cd362e-629f-4e68-92eb-e09c18f7855c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Clinical Trials of FTC+TAF with EVG+COBI in Treatment-Naïve Adults with HIV-1 Infection</content>
                              </paragraph>
                              <paragraph>In pooled 48-week trials of antiretroviral treatment-naïve HIV-1 infected adult subjects, the most common adverse reaction in subjects treated with FTC+TAF with EVG+COBI (N=866) (incidence greater than or equal to 10%, all grades) was nausea (10%). In this treatment group, 0.9% of subjects discontinued FTC+TAF with EVG+COBI due to adverse events during the 48-week treatment period <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. The safety profile was similar in virologically-suppressed adults with HIV-1 infection who were switched to FTC+TAF with EVG+COBI (N=799). Antiretroviral treatment-naïve adult subjects treated with FTC+TAF with EVG+COBI experienced mean increases of 30 mg/dL of total cholesterol, 15 mg/dL of LDL cholesterol, 7 mg/dL of HDL cholesterol and 29 mg/dL of triglycerides after 48 weeks of use.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="611f0a22-31dc-4d9c-bfdd-1dfa2d3abee7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Laboratory Tests</content>
                                    </paragraph>
                                    <paragraph>In two 48-week trials in antiretroviral treatment-naïve HIV-1 infected adults treated with FTC+TAF with EVG+COBI (N=866) with a median baseline eGFR of 115 mL per minute, mean serum creatinine increased by 0.1 mg per dL from baseline to Week 48. Median urine protein-to-creatinine ratio (UPCR) was 44 mg per gram at baseline and at Week 48. In a 48-week trial in virologically-suppressed TDF-treated adults who switched to FTC+TAF with EVG+COBI (N=959) with a mean baseline eGFR of 112 mL per minute, mean serum creatinine was similar to baseline and median UPCR was 61 mg per gram at baseline and 46 mg per gram at Week 48. In a 24-week trial in adults with renal impairment (baseline eGFR 30 to 69 mL per minute) who received FTC+TAF with EVG+COBI (N=248), mean serum creatinine was 1.5 mg per dL at both baseline and Week 24. Median UPCR was 161 mg per gram at baseline and 93 mg per gram at Week 24.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9baa6245-95b9-42a0-a0dc-d7c77305dbf9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bone Mineral Density Effects</content>
                                    </paragraph>
                                    <paragraph>In the pooled analysis of two 48-week trials of antiretroviral treatment-naïve HIV-1 infected adult subjects, bone mineral density (BMD) from baseline to Week 48 was assessed by dual-energy X-ray absorptiometry (DXA). Mean BMD decreased from baseline to Week 48 −1.30% with FTC+TAF with EVG+COBI at the lumbar spine and −0.66% at the total hip. BMD declines of 5% or greater at the lumbar spine were experienced by 10% of FTC+TAF with EVG+COBI subjects. BMD declines of 7% or greater at the femoral neck were experienced by 7% of FTC+TAF with EVG+COBI subjects. The long-term clinical significance of these BMD changes is not known. Fractures (excluding fingers and toes) were reported in 7 (0.8%) subjects in the FTC+TAF with EVG+COBI group.</paragraph>
                                    <paragraph>In 799 virologically-suppressed TDF-treated adult subjects that switched to FTC+TAF with EVG+COBI, at Week 48 mean BMD increased (1.86% lumbar spine, 1.95% total hip). BMD declines of 5% or greater at the lumbar spine were experienced by 1% of FTC+TAF with EVG+COBI subjects. BMD declines of 7% or greater at the femoral neck were experienced by 1% of FTC+TAF with EVG+COBI subjects.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5f240ba1-de16-4ad0-a599-13ba3bc9deeb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Clinical Trials in Pediatric Subjects with HIV-1 Infection</content>
                              </paragraph>
                              <paragraph>In a 24 week, open-label trial of 23 antiretroviral treatment-naïve HIV-1 infected pediatric subjects aged 12 to less than 18 years old (weighing at least 35 kg) who received FTC+TAF with EVG+COBI, the safety of this combination was similar to that of adults. Among these pediatric subjects, mean BMD increased from baseline to Week 24, +1.7% at the lumbar spine and +0.8% for the total body less head. Mean changes from baseline BMD Z-scores were −0.10 for lumbar spine and −0.11 for total body less head at Week 24. Two subjects had significant (greater than 4%) lumbar spine BMD loss at Week 24.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="5b760329-078e-4511-aa9e-a190c6319c02"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Consult the Full Prescribing Information prior to and during treatment for potential drug interactions. (<linkHtml href="#S7">7</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="3b14fdbc-96da-4421-8537-ab0be1ac67b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1       Potential for Other Drugs to Affect One or More Components of DESCOVY</title>
                     <text>
                        <paragraph>TAF, a component of DESCOVY, is a substrate of P-gp, BCRP, OATP1B1, and OATP1B3. Drugs that strongly affect P-gp activity may lead to changes in TAF absorption (see <linkHtml href="#t1">Table 1</linkHtml>). Drugs that induce P-gp activity are expected to decrease the absorption of TAF, resulting in decreased plasma concentration of TAF, which may lead to loss of therapeutic effect of DESCOVY and development of resistance. Coadministration of DESCOVY with other drugs that inhibit P-gp may increase the absorption and plasma concentration of TAF. TAF is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or UGT1A1. TAF is a weak inhibitor of CYP3A <content styleCode="italics">in vitro</content>. TAF is not an inhibitor or inducer of CYP3A <content styleCode="italics">in vivo</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="b0f44bf5-ce5e-4850-952c-5dc79abe64dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2       Drugs Affecting Renal Function</title>
                     <text>
                        <paragraph>Because FTC and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of DESCOVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC, tenofovir, and other renally eliminated drugs and this may increase the risk of adverse reactions. Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="f8d84d53-e2d9-4118-9c29-f10047f89e40"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3       Established and Other Potentially Significant Interactions</title>
                     <text>
                        <paragraph>Table 1 provides a listing of established or potentially clinically significant drug interactions with recommended steps to prevent or manage the drug interaction (the table is not all inclusive). The drug interactions described are based on studies conducted with either DESCOVY, the components of DESCOVY (emtricitabine and tenofovir alafenamide) as individual agents, or are predicted drug interactions that may occur with DESCOVY. For magnitude of interaction, <content styleCode="italics">see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>.</paragraph>
                        <table ID="t1" width="75%">
                           <caption>Table 1          Established and Other Potentially Significant<footnote>This table is not all inclusive.</footnote> Drug Interactions</caption>
                           <col align="left" valign="top" width="25%"/>
                           <col align="left" valign="top" width="25%"/>
                           <col align="left" valign="top" width="50%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Lrule Rrule">Concomitant Drug Class: Drug Name</th>
                                 <th align="center" styleCode="Rrule" valign="middle">Effect on Concentration<footnote> ↓=Decrease</footnote>
                                 </th>
                                 <th align="center" styleCode="Rrule" valign="middle">Clinical Comment</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antiretroviral Agents: Protease Inhibitors (PI)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">tipranavir/ritonavir</td>
                                 <td styleCode="Rrule">↓ TAF</td>
                                 <td styleCode="Rrule">Coadministration with DESCOVY is not recommended.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Other Agents</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anticonvulsants:</content>
                                    <br/>carbamazepine<br/>oxcarbazepine<br/>phenobarbital<br/>phenytoin</td>
                                 <td styleCode="Rrule">↓ TAF</td>
                                 <td styleCode="Rrule">Consider alternative anticonvulsant.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antimycobacterials: </content>
                                    <br/>rifabutin<br/>rifampin<br/>rifapentine</td>
                                 <td styleCode="Rrule">↓ TAF</td>
                                 <td styleCode="Rrule">Coadministration of DESCOVY with rifabutin, rifampin, or rifapentine is not recommended.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Herbal Products: </content>
                                    <br/>St. John's wort <content styleCode="italics">(Hypericum perforatum)</content>
                                 </td>
                                 <td styleCode="Rrule">↓ TAF</td>
                                 <td styleCode="Rrule">Coadministration of DESCOVY with St. John's wort is not recommended.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="c6005aad-14fb-4631-8a02-2e2605224430"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4       Drugs without Clinically Significant Interactions with DESCOVY</title>
                     <text>
                        <paragraph>Based on drug interaction studies conducted with the components of DESCOVY, no clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following antiretroviral agents: atazanavir with ritonavir or cobicistat, darunavir with ritonavir or cobicistat, dolutegravir, efavirenz, ledipasvir, lopinavir/ritonavir, maraviroc, nevirapine, raltegravir, rilpivirine, and sofosbuvir. No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="855237bb-7fcd-440c-9151-e972064c9202"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20160408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactation: Women infected with HIV should be instructed not to breastfeed, due to the potential for HIV transmission. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                           <item>Pediatrics: Not recommended for patients less than 12 years of age or weighing less than 35 kg. (<linkHtml href="#S8.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="ac8d56d8-0e33-4088-8ff0-fceedfe25097"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="9b7d386e-d44a-4507-8719-f2627fc73470"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DESCOVY during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7da4e21b-2922-4586-8224-2b371c0d8e9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary </content>
                              </paragraph>
                              <paragraph>There are insufficient human data on the use of DESCOVY during pregnancy to inform a drug-associated risk of birth defects and miscarriage. Tenofovir alafenamide (TAF) use in women during pregnancy has not been evaluated; however, emtricitabine (FTC) use during pregnancy has been evaluated in a limited number of women reported to the APR. Available data from the APR show no difference in the risk of overall major birth defects for FTC (2.4%) compared with the background rate for major birth defects of 2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in the clinically recognized pregnancies in the U.S. general population is 15−20%. In animal studies, no adverse developmental effects were observed when the components of DESCOVY were administered separately during the period of organogenesis at exposures 60 and 108 times (mice and rabbits, respectively) the FTC exposure and at exposure equal to or 53 times (rats and rabbits, respectively) the TAF exposure at the recommended daily dose of DESCOVY <content styleCode="italics">[see <linkHtml href="#data1">Data (8.1)</linkHtml>].</content> Likewise, no adverse developmental effects were seen when FTC was administered to mice through lactation at exposures up to approximately 60 times the exposure at the recommended daily dose of DESCOVY. No adverse effects were observed in the offspring when TDF was administered through lactation at tenofovir exposures of approximately 14 times the exposure at the recommended daily dosage of DESCOVY.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data1">
                           <id root="2969a994-a1d6-481c-b7e5-ec28b57c148f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="ca75e0d6-08bb-4f2d-b658-19c4c8e48a3b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                                 <component>
                                    <section>
                                       <id root="bd4b2a4f-7094-4271-b421-30e8bd7cd934"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Emtricitabine: Based on prospective reports to the APR through July 2015 of 2933 exposures to FTC-containing regimens during pregnancy (including 1984 exposed in the first trimester and 949 exposed in the second/third trimester), there was no difference between FTC and overall birth defects compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of birth defects in live births was 2.4% (95% CI: 1.7% to 3.1%) with first trimester exposure to FTC-containing regimens and 2.1% (95% CI: 1.3% to 3.2%) with the second/third trimester exposure to FTC-containing regimens.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="b62486b3-5ed4-426e-9d69-966544f2bb5d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                                 <component>
                                    <section>
                                       <id root="a852516c-418f-4cd1-97b5-dd9365660305"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Emtricitabine: FTC was administered orally to pregnant mice (250, 500, or 1000 mg/kg/day) and rabbits (100, 300, or 1000 mg/kg/day) through organogenesis (on gestation days 6 through 15, and 7 through 19, respectively). No significant toxicological effects were observed in embryo-fetal toxicity studies performed with FTC in mice at exposures (area under the curve [AUC]) approximately 60 times higher and in rabbits at approximately 108 times higher than human exposures at the recommended daily dose. In a pre/postnatal development study with FTC, mice were administered doses up to 1000 mg/kg/day; no significant adverse effects directly related to drug were observed in the offspring exposed daily from before birth (<content styleCode="italics">in utero</content>) through sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended daily dose.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="ed878799-6127-443e-9d4d-21c6b6cfcdcd"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Tenofovir Alafenamide: TAF was administered orally to pregnant rats (25, 100, or 250 mg/kg/day) and rabbits (10, 30, or 100 mg/kg/day) through organogenesis (on gestation days 6 through 17, and 7 through 20, respectively). No adverse embryo-fetal effects were observed in rats and rabbits at TAF exposures approximately similar to (rats) and 53 (rabbits) times higher than the exposure in humans at the recommended daily dose of DESCOVY. TAF is rapidly converted to tenofovir; the observed tenofovir exposures in rats and rabbits were 59 (rats) and 93 (rabbits) times higher than human tenofovir exposures at the recommended daily dose. Since TAF is rapidly converted to tenofovir and a lower tenofovir exposure in rats and mice was observed after TAF administration compared to tenofovir disoproxil fumarate (TDF, another prodrug for tenofovir) administration, a pre/postnatal development study in rats was conducted only with TDF. Doses up to 600 mg/kg/day were administered through lactation; no adverse effects were observed in the offspring on gestation day 7 [and lactation day 20] at tenofovir exposures of approximately 14 [21] times higher than the exposures in humans at the recommended daily dose of DESCOVY.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="fe1cc908-e344-4ff0-8944-6e0a31cd5d70"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="ccc43f2e-256c-4f63-8beb-f962210b7f96"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary </content>
                              </paragraph>
                              <paragraph>The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants, to avoid risking postnatal transmission of HIV.</paragraph>
                              <paragraph>FTC has been shown to be present in human breast milk; it is not known if TAF is present in human breast milk  <content styleCode="italics">[see <linkHtml href="#data">Data (8.2)</linkHtml>].</content> Tenofovir has been shown to be present in the milk of lactating rats and rhesus monkeys after administration of TDF <content styleCode="italics">[see <linkHtml href="#data">Data (8.2)</linkHtml>]</content>. It is not known if TAF can be present in animal milk. While it is not known whether TAF is present in human breast milk, FTC has been shown to be present in human breast milk <content styleCode="italics">[see <linkHtml href="#data">Data (8.2)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>It is not known if DESCOVY affects milk production or has effects on the breastfed child. Because of the potential for: 1) HIV transmission (in HIV-negative infants); 2) developing viral resistance (in HIV-positive infants); and 3) adverse reactions in a breastfed infant similar to those seen in adults, instruct mothers not to breastfeed if they are receiving DESCOVY <content styleCode="italics">[see <linkHtml href="#data">Data (8.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="399756ad-00ef-4836-8cd8-895f774c327d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="40934e62-17af-4def-a78c-7076eba54461"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                                 <component>
                                    <section>
                                       <id root="e14be310-3efd-468c-82bd-5ba8cba60a9c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Emtricitabine: Samples of breast milk obtained from five HIV-1 infected mothers show that emtricitabine is present in human milk. Breastfeeding infants whose mothers are being treated with emtricitabine may be at risk for developing viral resistance to emtricitabine. Other emtricitabine-associated risks in infants breastfed by mothers being treated with emtricitabine are unknown.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="37cac0bc-94c1-46ef-9c4b-a1fd32b90586"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                                 <component>
                                    <section>
                                       <id root="3ee7e87d-6481-49a0-9d0b-d3b57c32052f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Tenofovir Alafenamide: Studies in rats and monkeys have demonstrated that tenofovir is secreted in milk. Tenofovir was excreted into the milk of lactating rats following oral administration of TDF (up to 600 mg/kg/day) at up to approximately 24% of the median plasma concentration in the highest dosed animals at lactation day 11 <content styleCode="italics">[see <linkHtml href="#data1">Data (8.1)</linkHtml>]. </content>Tenofovir was excreted into the milk of lactating monkeys following a single subcutaneous (30 mg/kg) dose of tenofovir at concentrations up to approximately 4% of plasma concentration, resulting in exposure (AUC) of approximately 20% of plasma exposure.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="c7b93cf1-92f5-4c24-9e69-3b5093acf02a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The efficacy and safety of DESCOVY, in combination with other antiretroviral agents, for the treatment of HIV-1 infection was established in pediatric patents aged 12 years old and older with body weight greater than or equal to 35 kg <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>. Use of DESCOVY in this age group is supported by adequate and well controlled studies of FTC+TAF with EVG+COBI in adults and by a 24-week open-label trial of 23 antiretroviral treatment-naïve HIV-1 infected pediatric subjects 12 to less than 18 years old (weighing at least 35 kg) treated with FTC+TAF with EVG+COBI. The safety and efficacy of FTC+TAF with EVG+COBI was similar to that of antiretroviral treatment-naïve HIV-1 infected adults on this regimen <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. </paragraph>
                        <paragraph>Safety and effectiveness of DESCOVY in pediatric patients less than 12 years of age or less than 35 kg have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="b6ed73c9-4bca-4458-936e-535b6478ab17"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In clinical trials, 80 of the 97 subjects enrolled aged 65 years and over received FTC+TAF and EVG+COBI. No differences in safety or efficacy have been observed between elderly subjects and those between 12 and less than 65 years of age. </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="41aac90e-6e79-4a5d-aee5-e7aeeb8aef3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6       Renal Impairment</title>
                     <text>
                        <paragraph>DESCOVY is not recommended in patients with severe renal impairment (estimated creatinine clearance below 30 mL per minute). No dosage adjustment of DESCOVY is recommended in patients with estimated creatinine clearance greater than or equal to 30 mL per minute <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="1c36cd43-30d2-46f9-9468-f83d25f409f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7       Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of DESCOVY is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. DESCOVY has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="6c1b1bb9-2533-40e2-9dbb-55985064d8b7"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>No data are available on overdose of DESCOVY in patients. If overdose occurs, monitor the patient for evidence of toxicity. Treatment of overdose with DESCOVY consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <component>
                  <section>
                     <id root="337087a2-7893-41fe-aa76-ee1475647af9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Emtricitabine (FTC):</content> Limited clinical experience is available at doses higher than the recommended dose of FTC in DESCOVY. In one clinical pharmacology study, single doses of FTC 1200 mg (6 times the FTC dose in DESCOVY) were administered to 11 subjects. No severe adverse reactions were reported. The effects of higher doses are not known.</paragraph>
                        <paragraph>Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL per minute and a dialysate flow rate of 600 mL per minute). It is not known whether FTC can be removed by peritoneal dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0f8921a2-aae7-4786-9c69-c05c91b8883f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Tenofovir alafenamide (TAF)</content>: Limited clinical experience is available at doses higher than the recommended dose of TAF. A single dose of 125 mg TAF (5 times the TAF dose in 200/25 mg DESCOVY) was administered to 48 healthy subjects; no serious adverse reactions were reported. The effects of higher doses are unknown. Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="1287af46-a685-4e84-b8c4-c59eba1f4484"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>DESCOVY (emtricitabine and tenofovir alafenamide) is a fixed dose combination tablet containing emtricitabine (FTC) and tenofovir alafenamide (TAF) for oral administration.</paragraph>
                  <list listType="unordered">
                     <item>FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI).</item>
                     <item>TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate.</item>
                  </list>
                  <paragraph>Each 200/25 mg tablet contains 200 mg of FTC and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <component>
                  <section>
                     <id root="9266132c-a92e-47dd-b4be-779628f0768f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Emtricitabine:</content> The chemical name of FTC is 4-amino-5-fluoro-1-(2<content styleCode="italics">R</content>-hydroxymethyl-1,3-oxathiolan-5<content styleCode="italics">S</content>-yl)-(1H)-pyrimidin-2-one. FTC is the (-)enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5 position.</paragraph>
                        <paragraph>FTC has a molecular formula of C<sub>8</sub>H<sub>10</sub>FN<sub>3</sub>O<sub>3</sub>S and a molecular weight of 247.24 and has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM1"/>
                        </paragraph>
                        <paragraph>FTC is a white to off-white powder with a solubility of approximately 112 mg per mL in water at 25 °C. </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Chemical Structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="descovy-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0c05e8ab-8dc1-4608-87c3-5a68a9f2315c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Tenofovir alafenamide:</content> The chemical name of tenofovir alafenamide fumarate drug substance is L-alanine, <content styleCode="italics">N</content>-[(<content styleCode="italics">S</content>)-[[(1<content styleCode="italics">R</content>)-2-(6-amino-9<content styleCode="italics">H</content>-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester, (2<content styleCode="italics">E</content>)-2-butenedioate (2:1).</paragraph>
                        <paragraph>Tenofovir alafenamide fumarate has an empirical formula of C<sub>21</sub>H<sub>29</sub>O<sub>5</sub>N<sub>6</sub>P∙½(C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>) and a formula weight of 534.50 and has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                        <paragraph>Tenofovir alafenamide fumarate is a white to off-white or tan powder with a solubility of 4.7 mg per mL in water at 20 °C.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Chemical Structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="descovy-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="0b3c1ed8-d17c-46be-abf8-ce778e50b947"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160408"/>
               <component>
                  <section ID="S12.1">
                     <id root="6d6a93c9-3fd4-4724-a7ea-2dceea8f9119"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>DESCOVY is a fixed dose combination of antiretroviral drugs emtricitabine (FTC) and tenofovir alafenamide (TAF) <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="66254d67-7647-4821-ac31-c86caa2809a2"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="c0a115c3-b498-4b0e-bf7d-f8a4d6738c81"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>In a thorough QT/QTc study in 48 healthy subjects, TAF at the recommended dose or at a dose approximately 5 times the recommended dose, did not affect the QT/QTc interval and did not prolong the PR interval. The effect of the other component of DESCOVY, FTC, or the combination of FTC and TAF on the QT interval is not known.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="25009920-14c1-4bac-8910-5256f6487781"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="0fd66b1f-551e-4167-a68e-231d04d8da3b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption, Distribution, Metabolism, and Excretion</content>
                              </paragraph>
                              <paragraph>The pharmacokinetic (PK) properties of the components of DESCOVY are provided in Table 2. The multiple dose PK parameters of FTC and TAF and its metabolite tenofovir are provided in Table 3.</paragraph>
                              <table width="75%">
                                 <caption>Table 2          Pharmacokinetic Properties of the Components of DESCOVY</caption>
                                 <col align="left" valign="middle" width="34%"/>
                                 <col align="center" valign="middle" width="33%"/>
                                 <col align="center" valign="middle" width="33%"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Emtricitabine</th>
                                       <th styleCode="Rrule">Tenofovir Alafenamide</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="3">PBMCs=peripheral blood mononuclear cells; CES1=carboxylesterase 1</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Absorption</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">T<sub>max</sub> (h)</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Effect of high fat meal (relative to fasting)<footnote>Values refer to geometric mean ratio [High-fat meal/ fasting] in PK parameters and (90% confidence interval). High-calorie/high-fat meal = ~800  kcal, 50% fat.</footnote>
                                       </td>
                                       <td styleCode="Rrule">AUC Ratio = 0.91 (0.89, 0.93)<br/>C<sub>max</sub> Ratio = 0.74 (0.69, 0.78)</td>
                                       <td styleCode="Rrule">AUC Ratio = 1.75 (1.64, 1.88)<br/>C<sub>max </sub>Ratio= 0.85 (0.75, 0.95)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Distribution</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">% Bound to human plasma proteins</td>
                                       <td styleCode="Rrule">&lt;4</td>
                                       <td styleCode="Rrule">~80</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Source of protein binding data</td>
                                       <td styleCode="Rrule">
                                          <content styleCode="italics">In vitro</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="italics">Ex vivo</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood-to-plasma ratio</td>
                                       <td styleCode="Rrule">0.6</td>
                                       <td styleCode="Rrule">1.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Metabolism</td>
                                       <td styleCode="Rrule">Not significantly metabolized</td>
                                       <td styleCode="Rrule">Cathepsin A<footnote>
                                             <content styleCode="italics">In vivo</content>, TAF is hydrolyzed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite, tenofovir diphosphate. <content styleCode="italics">In vitro</content> studies have shown that TAF is metabolized to tenofovir by cathepsin A in PBMCs and macrophages; and by CES1 in hepatocytes. Upon coadministration with the moderate CYP3A inducer probe efavirenz, TAF exposure was unaffected.</footnote> (PBMCs)<br/>CES1 (hepatocytes)<br/>CYP3A (minimal)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Elimination</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Major route of elimination</td>
                                       <td styleCode="Rrule">Glomerular filtration and active tubular secretion</td>
                                       <td styleCode="Rrule">Metabolism (&gt;80% of oral dose)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">t<sub>1/2</sub> (h)<footnote>t<sub>1/2</sub> values refer to median terminal plasma half-life. Note that the pharmacologically active metabolite, tenofovir diphosphate, has a half-life of 150–180 hours within PBMCs.</footnote>
                                       </td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.51</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">% Of dose excreted in urine<footnote ID="t2f1">Dosing in mass balance studies: FTC (single dose administration of [<sup>14</sup>C] emtricitabine after multiple dosing of emtricitabine for ten days); TAF (single dose administration of [<sup>14</sup>C] tenofovir alafenamide).</footnote>
                                       </td>
                                       <td styleCode="Rrule">70</td>
                                       <td styleCode="Rrule">&lt;1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">% Of dose excreted in feces<footnoteRef IDREF="t2f1"/>
                                       </td>
                                       <td styleCode="Rrule">13.7</td>
                                       <td styleCode="Rrule">31.7</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="75%">
                                 <caption>Table 3          Multiple Dose PK Parameters of Emtricitabine, Tenofovir Alafenamide and its Metabolite Tenofovir Following Oral Administration with Food in HIV-Infected Adults</caption>
                                 <col align="left" valign="middle" width="25%"/>
                                 <col align="center" valign="middle" width="25%"/>
                                 <col align="center" valign="middle" width="25%"/>
                                 <col align="center" valign="middle" width="25%"/>
                                 <thead>
                                    <tr>
                                       <th align="center" styleCode="Lrule Rrule">Parameter<br/>Mean (CV%)</th>
                                       <th styleCode="Rrule" valign="bottom">Emtricitabine<footnote>From Intensive PK analysis in a phase 2 trial in HIV infected adults treated with FTC+TAF and EVG+COBI.</footnote>
                                       </th>
                                       <th styleCode="Rrule" valign="bottom">Tenofovir Alafenamide<footnote>From Population PK analysis in two trials of treatment-naïve adults with HIV-1 infection treated with FTC+TAF with EVG+COBI (N=539).</footnote>
                                       </th>
                                       <th styleCode="Rrule" valign="bottom">Tenofovir<footnote>From Population PK analysis in two trials of treatment-naïve adults with HIV-1 infection treated with FTC+TAF with EVG+COBI (N=841).</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="4">CV=Coefficient of Variation; NA=Not Applicable</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>max</sub>
                                          <br/>(microgram per mL)</td>
                                       <td styleCode="Rrule">2.1 (20.2)</td>
                                       <td styleCode="Rrule">0.16 (51.1)</td>
                                       <td styleCode="Rrule">0.02 (26.1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AUC<sub>tau</sub>
                                          <br/>(microgram∙hour per mL)</td>
                                       <td styleCode="Rrule">11.7 (16.6)</td>
                                       <td styleCode="Rrule">0.21 (71.8)</td>
                                       <td styleCode="Rrule">0.29 (27.4)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">C<sub>trough</sub>
                                          <br/>(microgram per mL)</td>
                                       <td styleCode="Rrule">0.10 (46.7)</td>
                                       <td styleCode="Rrule">NA</td>
                                       <td styleCode="Rrule">0.01 (28.5)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4ed4421d-3d63-4fa6-bbb4-fb2cecc37602"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="ed7fc92d-14c2-4512-a867-c35214a3895a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of FTC+TAF combined with EVG+COBI in HIV infected subjects with renal impairment (eGFR 30 to 69 mL per minute by Cockcroft-Gault method) were evaluated in a subset of virologically-suppressed subjects in an open-label trial (Table 4).</paragraph>
                                    <table width="75%">
                                       <caption>Table 4          Pharmacokinetics of the Components of DESCOVY and a Metabolite of TAF (Tenofovir) in HIV-Infected Adults with Renal Impairment Compared to Subjects with Normal Renal Function<footnote>Trial in HIV infected adults with renal impairment treated with FTC+TAF with EVG+COBI.</footnote>
                                       </caption>
                                       <col align="left" valign="middle" width="25%"/>
                                       <col align="center" valign="middle" width="25%"/>
                                       <col align="center" valign="middle" width="25%"/>
                                       <col align="center" valign="middle" width="25%"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule"/>
                                             <th colspan="3" styleCode="Rrule">AUC<sub>tau </sub>(microgram∙hour per mL)<br/>Mean (CV%)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Creatinine Clearance </th>
                                             <th styleCode="Rrule">≥90 mL per minute (N=18)<footnote>From a phase 2 trial in HIV-infected adults with normal renal function treated with FTC+TAF with EVG+COBI.</footnote>
                                             </th>
                                             <th styleCode="Rrule">60–89 mL per minute (N=11)<footnote>These subjects had an eGFR ranging from 60 to 69 mL per minute.</footnote>
                                             </th>
                                             <th styleCode="Rrule">30–59 mL per minute (N=18)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Emtricitabine</td>
                                             <td styleCode="Rrule">11.4 (11.9)</td>
                                             <td styleCode="Rrule">17.6 (18.2)</td>
                                             <td styleCode="Rrule">23.0 (23.6)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Tenofovir Alafenamide<footnote>AUC<sub>last</sub>
                                                </footnote>
                                             </td>
                                             <td styleCode="Rrule">0.23 (47.2)</td>
                                             <td styleCode="Rrule">0.24 (45.6)</td>
                                             <td styleCode="Rrule">0.26 (58.8)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Tenofovir</td>
                                             <td styleCode="Rrule">0.32 (14.9)</td>
                                             <td styleCode="Rrule">0.46 (31.5)</td>
                                             <td styleCode="Rrule">0.61 (28.4)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1531f65c-38a9-4972-917b-ad2173c800a5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                                 <component>
                                    <section>
                                       <id root="7b0c33d7-87b8-42a8-be84-5a04527bb7ef"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine:</content> The pharmacokinetics of FTC has not been studied in subjects with hepatic impairment; however, FTC is not significantly metabolized by liver enzymes, so the impact of hepatic impairment should be limited.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="a090a692-e41a-47a5-8ac4-718a3b3e4c75"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Tenofovir Alafenamide:</content> Clinically relevant changes in tenofovir pharmacokinetics in subjects with hepatic impairment were not observed in subjects with mild to moderate (Child-Pugh Class A and B) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3ee3367c-81b3-4d88-b30f-457aa1ace250"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatitis B and/or Hepatitis C Virus Coinfection</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of FTC and TAF have not been fully evaluated in subjects coinfected with hepatitis B and/or C virus.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7a08ee49-76c9-4527-840e-68c39463f74c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>Exposures of FTC and TAF in 24 pediatric subjects aged 12 to less than 18 years who received FTC+TAF and EVG+COBI were decreased (23% for AUC) compared to exposures achieved in treatment-naïve adults following administration of this dosage regimen <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>. These exposure differences are not thought to be clinically significant based on exposure-response relationships.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="62f4d080-2765-4166-abe4-cd265a14de07"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients </content>
                                    </paragraph>
                                    <paragraph>Pharmacokinetics of FTC and TAF have not been fully evaluated in the elderly (65 years of age and older). Population pharmacokinetics analysis of HIV-infected subjects in Phase 2 and Phase 3 trials of FTC+TAF and EVG+COBI showed that age did not have a clinically relevant effect on exposures of TAF up to 75 years of age <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7325c7b0-3964-46f8-9ed2-b9ef46b55fd9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race</content>
                                    </paragraph>
                                    <paragraph>Based on population pharmacokinetic analyses, no dosage adjustment is recommended based on race.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5a634b0f-2e22-400c-b17a-89be2a4ce320"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Gender</content>
                                    </paragraph>
                                    <paragraph>Based on population pharmacokinetic analyses, no dosage adjustment is recommended based on gender.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a1a8d7ea-dfb9-4be8-8f75-a4355489ba4a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>The effects of coadministered drugs on the exposure of TAF are shown in Table 5 and the effects of DESCOVY or its components on the exposure of coadministered drugs are shown in Table 6 [these studies were conducted with DESCOVY or the components of DESCOVY (FTC or TAF) administered alone]. For information regarding clinical recommendations, see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>.</paragraph>
                              <table width="90%">
                                 <caption>Table 5          Drug Interactions: Changes in TAF Pharmacokinetic Parameters in the Presence of Coadministered Drug(s)<footnote> All interaction studies conducted in healthy volunteers.</footnote>
                                 </caption>
                                 <col align="left" valign="middle" width="18%"/>
                                 <col align="center" valign="middle" width="17%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <thead>
                                    <tr>
                                       <th align="center" rowspan="2" styleCode="Lrule Rrule">Coadministered Drug</th>
                                       <th rowspan="2" styleCode="Rrule">Coadministered Drug(s)  Dosage (once daily)<br/>(mg)</th>
                                       <th rowspan="2" styleCode="Rrule">Tenofovir Alafenamide  Dosage (once daily)<br/>(mg)</th>
                                       <th rowspan="2" styleCode="Rrule">N</th>
                                       <th colspan="3" styleCode="Botrule Rrule">Mean Ratio of TAF PK Parameters (90%  CI);<br/>No effect = 1.00</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">AUC</th>
                                       <th styleCode="Rrule">C<sub>min</sub>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="7">NC=Not Calculated</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Atazanavir</td>
                                       <td styleCode="Rrule">300 (+100 ritonavir)</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.77<br/>(1.28, 2.44)</td>
                                       <td styleCode="Rrule">1.91<br/>(1.55, 2.35)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cobicistat</td>
                                       <td styleCode="Rrule">150</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">2.83<br/>(2.20, 3.65)</td>
                                       <td styleCode="Rrule">2.65<br/>(2.29, 3.07)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Darunavir</td>
                                       <td styleCode="Rrule">800 (+150 cobicistat)</td>
                                       <td styleCode="Rrule">25<footnote ID="t5f1">Study conducted with DESCOVY (FTC/TAF).</footnote>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0.93<br/>(0.72, 1.21)</td>
                                       <td styleCode="Rrule">0.98<br/>(0.80, 1.19)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Darunavir</td>
                                       <td styleCode="Rrule">800 (+100 ritonavir) </td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.42<br/>(0.96, 2.09)</td>
                                       <td styleCode="Rrule">1.06<br/>(0.84, 1.35)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dolutegravir</td>
                                       <td styleCode="Rrule">50</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">1.24<br/>(0.88, 1.74)</td>
                                       <td styleCode="Rrule">1.19<br/>(0.96, 1.48)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Efavirenz</td>
                                       <td styleCode="Rrule">600</td>
                                       <td styleCode="Rrule">40<footnoteRef IDREF="t5f1"/>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0.78<br/>(0.58, 1.05)</td>
                                       <td styleCode="Rrule">0.86<br/>(0.72, 1.02)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Lopinavir</td>
                                       <td styleCode="Rrule">800 (+200 ritonavir)</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">2.19<br/>(1.72, 2.79)</td>
                                       <td styleCode="Rrule">1.47<br/>(1.17, 1.85)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rilpivirine</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">17</td>
                                       <td styleCode="Rrule">1.01<br/>(0.84, 1.22)</td>
                                       <td styleCode="Rrule">1.01<br/>(0.94, 1.09)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Sertraline</td>
                                       <td styleCode="Rrule">50 (dosed as a single dose)</td>
                                       <td styleCode="Rrule">10 <footnote>Study conducted with FTC+TAF with EVG+COBI.</footnote>
                                       </td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">1.00<br/>(0.86, 1.16)</td>
                                       <td styleCode="Rrule">0.96<br/>(0.89, 1.03)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="90%">
                                 <caption>Table 6          Drug Interactions: Changes in PK Parameters for Coadministered Drug in the Presence of DESCOVY or the Individual Components<footnote>All interaction studies conducted in healthy volunteers.</footnote>
                                 </caption>
                                 <col align="left" valign="middle" width="18%"/>
                                 <col align="center" valign="middle" width="17%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <col align="center" valign="middle" width="9%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <col align="center" valign="middle" width="14%"/>
                                 <thead>
                                    <tr>
                                       <th align="center" rowspan="2" styleCode="Lrule Rrule">Coadministered  Drug</th>
                                       <th rowspan="2" styleCode="Rrule">Coadministered Drug Dosage (once daily)<br/>(mg)</th>
                                       <th rowspan="2" styleCode="Rrule">Tenofovir  Alafenamide Dosage (once daily) <br/>(mg)</th>
                                       <th rowspan="2" styleCode="Rrule">N</th>
                                       <th colspan="3" styleCode="Botrule Rrule">Mean Ratio of  Coadministered Drug PK Parameters (90%  CI);  <br/>No effect = 1.00</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th align="center" styleCode="Rrule">C<sub>max</sub>
                                       </th>
                                       <th styleCode="Rrule">AUC</th>
                                       <th styleCode="Rrule">C<sub>min</sub>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="7">NC=Not Calculated</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Atazanavir</td>
                                       <td styleCode="Rrule">300 +100  ritonavir</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.98<br/>(0.89, 1.07)</td>
                                       <td styleCode="Rrule">0.99<br/>(0.96, 1.01)</td>
                                       <td styleCode="Rrule">1.00<br/>(0.96, 1.04)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cobicistat</td>
                                       <td styleCode="Rrule">150</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.06<br/>(1.00, 1.12)</td>
                                       <td styleCode="Rrule">1.09<br/>(1.03, 1.15)</td>
                                       <td styleCode="Rrule">1.11<br/>(0.98, 1.25)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Botrule">Darunavir</td>
                                       <td styleCode="Rrule">800 +150 cobicistat</td>
                                       <td styleCode="Rrule">25<footnote>Study conducted with DESCOVY (FTC/TAF).</footnote>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule Botrule">1.02<br/>(0.96, 1.09)</td>
                                       <td styleCode="Rrule Botrule">0.99<br/>(0.92, 1.07)</td>
                                       <td styleCode="Rrule Botrule">0.97<br/>(0.82, 1.15)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Botrule">Darunavir</td>
                                       <td styleCode="Rrule Toprule">800 +100 ritonavir</td>
                                       <td styleCode="Rrule Toprule">10</td>
                                       <td styleCode="Rrule Toprule">10</td>
                                       <td styleCode="Rrule Botrule">0.99<br/>(0.91, 1.08)</td>
                                       <td styleCode="Rrule Botrule">1.01<br/>(0.96, 1.06)</td>
                                       <td styleCode="Rrule Botrule">1.13<br/>(0.95, 1.34)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Botrule">Dolutegravir</td>
                                       <td styleCode="Rrule Toprule">50 mg</td>
                                       <td styleCode="Rrule Toprule">10</td>
                                       <td styleCode="Rrule Toprule">10</td>
                                       <td styleCode="Rrule Botrule">1.15<br/>(1.04, 1.27)</td>
                                       <td styleCode="Rrule Botrule">1.02<br/>(0.97, 1.08)</td>
                                       <td styleCode="Rrule Botrule">1.05<br/>(0.97, 1.13)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule Botrule">Lopinavir</td>
                                       <td styleCode="Rrule Toprule">800 +200 ritonavir</td>
                                       <td styleCode="Rrule Toprule">10</td>
                                       <td styleCode="Rrule Toprule">10</td>
                                       <td styleCode="Rrule Botrule">1.00<br/>(0.95, 1.06)</td>
                                       <td styleCode="Rrule Botrule">1.00<br/>(0.92, 1.09)</td>
                                       <td styleCode="Rrule Botrule">0.98<br/>(0.85, 1.12)</td>
                                    </tr>
                                    <tr>
                                       <td rowspan="2" styleCode="Lrule Rrule Botrule">Midazolam<footnote>A sensitive CYP3A4 substrate.</footnote>
                                       </td>
                                       <td styleCode="Rrule Toprule">2.5 (orally)</td>
                                       <td rowspan="2" styleCode="Rrule Toprule">25</td>
                                       <td rowspan="2" styleCode="Rrule Toprule">18</td>
                                       <td styleCode="Rrule Botrule">1.02<br/>(0.92, 1.13)</td>
                                       <td styleCode="Rrule Botrule">1.12<br/>(1.03, 1.22)</td>
                                       <td styleCode="Rrule Botrule">NC</td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Rrule Toprule">1 (intravenous)</td>
                                       <td align="center" styleCode="Rrule Botrule">0.99<br/>(0.89, 1.11)</td>
                                       <td align="center" styleCode="Rrule Botrule">1.08<br/>(1.04, 1.14)</td>
                                       <td styleCode="Rrule Botrule">NC</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rilpivirine</td>
                                       <td styleCode="Rrule Toprule">25</td>
                                       <td styleCode="Rrule Toprule">25</td>
                                       <td styleCode="Rrule Toprule">16</td>
                                       <td styleCode="Rrule">0.93<br/>(0.87, 0.99)</td>
                                       <td styleCode="Rrule">1.01<br/>(0.96, 1.06)</td>
                                       <td styleCode="Rrule">1.13<br/>(1.04, 1.23)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Sertraline</td>
                                       <td styleCode="Rrule">50 (dosed as a single dose)</td>
                                       <td styleCode="Rrule">10<footnote>Study conducted with FTC+TAF with EVG+COBI.</footnote>
                                       </td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">1.14<br/>(0.94, 1.38)</td>
                                       <td styleCode="Rrule">0.93<br/>(0.77, 1.13)</td>
                                       <td styleCode="Rrule">NC</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="bc0b2d13-8f2b-45e6-9fbf-9af9ea0acb49"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="b542bdeb-7eba-43cf-950f-aa9af75ace61"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="a72745d5-efe0-4eed-b3e2-c691f6ff3b84"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Emtricitabine:</content> FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5′-triphosphate is a weak inhibitor of mammalian DNA polymerases α, β, Ɛ, and mitochondrial DNA polymerase γ.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="25212162-4d40-46f5-a384-f61a98391dfa"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tenofovir Alafenamide:</content> TAF is a phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analog). Plasma exposure to TAF allows for permeation into cells and then TAF is intracellularly converted to tenofovir through hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular kinases to the active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV-1 replication through incorporation into viral DNA by the HIV reverse transcriptase, which results in DNA chain-termination. </paragraph>
                                    <paragraph>Tenofovir has activity against HIV-1. Cell culture studies have shown that both tenofovir and FTC can be fully phosphorylated when combined in cells. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4e3a52ca-5d68-47a0-b0d9-97a6c2f6412d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activity in Cell Culture</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="932a0b4a-c14b-46fa-b703-f10bf1c56367"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Emtricitabine:</content> The antiviral activity of FTC against laboratory and clinical isolates of HIV-1 was assessed in T lymphoblastoid cell lines, the MAGI-CCR5 cell line, and primary peripheral blood mononuclear cells. The EC<sub>50</sub> values for FTC were in the range of 0.0013–0.64 micromolar. FTC displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0.007–0.075 micromolar) and showed strain specific activity against HIV-2 (EC<sub>50</sub> values ranged from 0.007–1.5 micromolar).</paragraph>
                                    <paragraph>In a study of FTC with a broad panel of representatives from the major classes of approved anti-HIV agents (NRTIs, non-nucleoside reverse transcriptase inhibitors [NNRTIs], integrase strand transfer inhibitors [INSTIs], and PIs) no antagonism was observed for these combinations.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="bca21f97-c941-4aa8-ae1e-9173090e60de"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tenofovir Alafenamide:</content> The antiviral activity of TAF against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4-T lymphocytes. The EC<sub>50</sub> values for TAF ranged from 2.0 to 14.7 nM.</paragraph>
                                    <paragraph>TAF displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including sub-types A, B, C, D, E, F, and G (EC<sub>50</sub> values ranged from 0.10 to 12.0 nM) and strain specific activity against HIV-2 (EC<sub>50</sub> values ranged from 0.91 to 2.63 nM).</paragraph>
                                    <paragraph>In a study of TAF with a broad panel of representatives from the major classes of approved anti-HIV agents (NRTIs, NNRTIs, INSTIs, and PIs) no antagonism was observed for these combinations.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a231fcfc-0110-4694-be4f-b2c5cb1494a8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="c8f094c4-1f9d-4f15-9be1-e942e3500d61"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Cell Culture</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                                 <component>
                                    <section>
                                       <id root="8a9661bf-2a7d-4182-9996-81f4b1482dfa"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Emtricitabine:</content> HIV-1 isolates with reduced susceptibility to FTC were selected in cell culture and in subjects treated with FTC. Reduced susceptibility to FTC was associated with M184V or I substitutions in HIV-1 RT.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="199264ef-0a57-4de0-856c-221a130162d4"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Tenofovir Alafenamide:</content> HIV-1 isolates with reduced susceptibility to TAF were selected in cell culture. HIV-1 isolates selected by TAF expressed a K65R substitution in HIV-1 RT, sometimes in the presence of S68N or L429I substitutions; in addition, a K70E substitution in HIV-1 RT was observed.</paragraph>
                                       </text>
                                       <effectiveTime value="20160408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="af8a480d-efaf-4412-9043-d04e628f5b35"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Clinical Trials</content>
                                    </paragraph>
                                    <paragraph>The resistance profile of DESCOVY in combination with other antiretroviral agents for the treatment of HIV-1 infection is based on studies of FTC+TAF with EVG+COBI in the treatment of HIV-1 infection<content styleCode="italics">. </content>In a pooled analysis of antiretroviral-naïve subjects, genotyping was performed on plasma HIV-1 isolates from all subjects with HIV-1 RNA greater than 400 copies per mL at confirmed virologic failure, at Week 48, or at time of early study drug discontinuation. Genotypic resistance developed in 7 of 14 evaluable subjects. The resistance-associated substitutions that emerged were M184V/I (N=7) and K65R (N=1). Three subjects had virus with emergent R, H, or E at the polymorphic Q207 residue in reverse transcriptase.</paragraph>
                                    <paragraph>One subject was identified with emergent resistance to FTC or TAF (M184M/I) out of 4 virologic failure subjects in a clinical study of virologically-suppressed subjects who switched from a regimen containing FTC+TDF to FTC+TAF with EVG+COBI (N=799).</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="bcf279e8-7389-4208-8119-4c17b7d9fdc8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross-Resistance </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                           <component>
                              <section>
                                 <id root="d428c81e-7eb5-4904-8569-ee147e70f098"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Emtricitabine</content>: FTC-resistant viruses with the M184V or I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.</paragraph>
                                    <paragraph>Viruses harboring substitutions conferring reduced susceptibility to stavudine and zidovudine-thymidine analog substitutions (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) or didanosine (L74V) remained sensitive to FTC. HIV-1 containing the K103N substitution or other substitutions associated with resistance to NNRTIs was susceptible to FTC.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="e09d08c0-cf23-46c1-a42f-c5d7e46a57e6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tenofovir Alafenamide: </content>Tenofovir resistance substitutions K65R and K70E result in reduced susceptibility to abacavir, didanosine, emtricitabine, lamivudine, and tenofovir.</paragraph>
                                    <paragraph>HIV-1 with multiple thymidine analog substitutions (M41L, D67N, K70R, L210W, T215F/Y, K219Q/E/N/R), or multinucleoside resistant HIV-1 with a T69S double insertion mutation or with a Q151M substitution complex including K65R, showed reduced susceptibility to TAF in cell culture.</paragraph>
                                 </text>
                                 <effectiveTime value="20160408"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="619abd99-30cf-4f2e-9dee-715059961103"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20160408"/>
               <component>
                  <section ID="S13.1">
                     <id root="72e802b5-9216-431a-ab51-b7a39453c724"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20160408"/>
                     <component>
                        <section>
                           <id root="fbad4edd-6bc4-4529-ac37-d166727c41fb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Emtricitabine </content>
                              </paragraph>
                              <paragraph>In long-term carcinogenicity studies of FTC, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg per kg per day (23 times the human systemic exposure at the recommended dose of 200 mg per day in DESCOVY) or in rats at doses up to 600 mg per kg per day (28 times the human systemic exposure at the recommended dose in DESCOVY).</paragraph>
                              <paragraph>FTC was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or mouse micronucleus assays.</paragraph>
                              <paragraph>FTC did not affect fertility in male rats at approximately 140 times or in male and female mice at approximately 60 times higher exposures (AUC) than in humans given the recommended 200 mg daily dosage in DESCOVY. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60 times higher than human exposures at the recommended 200 mg daily dosage in DESCOVY.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="95331f66-ec36-4abf-80f3-880f4a76f4fc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tenofovir Alafenamide </content>
                              </paragraph>
                              <paragraph>Since TAF is rapidly converted to tenofovir and a lower tenofovir exposure in rats and mice was observed after TAF administration compared to TDF administration, carcinogenicity studies were conducted only with TDF. Long-term oral carcinogenicity studies of TDF in mice and rats were carried out at exposures up to approximately 10 times (mice) and 4 times (rats) those observed in humans at the recommended dose of TDF (300 mg) for HIV-1 infection. The tenofovir exposure in these studies was approximately 167 times (mice) and 55 times (rat) those observed in humans after administration of the daily recommended dose of DESCOVY. At the high dose in female mice, liver adenomas were increased at tenofovir exposures approximately 10 times (300 mg TDF) and 167 times (DESCOVY) the exposure observed in humans. In rats, the study was negative for carcinogenic findings.</paragraph>
                              <paragraph>TAF was not genotoxic in the reverse mutation bacterial test (Ames test), mouse lymphoma or rat micronucleus assays.</paragraph>
                              <paragraph>There were no effects on fertility, mating performance or early embryonic development when TAF was administered to male rats at a dose equivalent to 62 times (25 mg TAF) the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 14 days prior to mating through Day 7 of gestation.</paragraph>
                           </text>
                           <effectiveTime value="20160408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="3d0a25b6-2f81-4061-a159-e002ca007c78"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Minimal to slight infiltration of mononuclear cells in the posterior uvea was observed in dogs with similar severity after three and nine month administration of TAF; reversibility was seen after a three month recovery period. No eye toxicity was observed in the dog at systemic exposures of 5 (TAF) and 15 (tenofovir) times the exposure seen in humans with the recommended daily TAF dose in DESCOVY.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="bebe5d46-2b65-4b2f-8f64-5477e2479fa1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In trials of FTC+TAF with EVG+COBI in HIV-1 infected adults as initial therapy in those with no antiretroviral treatment history (N=866) and to replace a stable antiretroviral regimen in those who were virologically-suppressed for at least 6 months with no known resistance substitutions (N=799), 92% and 96% of patients in the two populations, respectively, had HIV-1 RNA less than 50 copies per mL at Week 48.</paragraph>
                  <paragraph>In a trial of FTC+TAF with EVG+COBI in 23 treatment-naïve HIV-1 infected pediatric patients aged 12 to less than 18 years old and weighing greater than 35 kg, the virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 91% at 24 weeks.</paragraph>
                  <paragraph>In a trial in 248 HIV-1 infected adult patients with estimated creatinine clearance greater than 30 mL per minute but less than 70 mL per minute, 95% (235/248) of the combined population of treatment-naïve subjects (N=6) began on FTC+TAF with EVG+COBI and those previously virologically-suppressed on other regimens (N=242) and switched to FTC+TAF with EVG+COBI had HIV-1 RNA less than 50 copies per mL at Week 24. </paragraph>
               </text>
               <effectiveTime value="20160408"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="3954d334-2b60-4d91-a488-cb302f4a3ba6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>DESCOVY 200 mg/25 mg tablets are blue, rectangular-shaped, and film-coated with "GSI" debossed on one side and "225" on the other side. Each bottle contains 30 tablets (NDC 61958-2002-1), a silica gel desiccant, polyester coil, and is closed with a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <component>
                  <section>
                     <id root="895fb356-a0e4-44f2-9751-b47ffd173064"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store below 30 °C (86 °F).</paragraph>
                        <list listType="unordered">
                           <item>Keep container tightly closed.</item>
                           <item>Dispense only in original container.</item>
                        </list>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="e5501837-6c9c-4f48-acd6-769a47a3df0a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20160408"/>
               <component>
                  <section>
                     <id root="1936eb52-9b92-41f4-ad55-535b6a70c7da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactic Acidosis</content>
                        </paragraph>
                        <paragraph>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with use of drugs similar to DESCOVY. Advise patients that they should stop DESCOVY if they develop clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9ae083ae-7e8e-4a3b-9c34-29325b511681"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Post-treatment Acute Exacerbation of Hepatitis B in Patients with HBV Coinfection</content>
                        </paragraph>
                        <paragraph>Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued products containing FTC and/or TDF, and may likewise occur with discontinuation of DESCOVY <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. Advise the patient to not discontinue DESCOVY without first informing their healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b653b14a-f0a6-4913-b353-1f6e984cc191"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fat Redistribution</content>
                        </paragraph>
                        <paragraph>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bb29995d-7e39-41af-87cd-85f87a3654a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Immune Reconstitution Syndrome</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e11b071d-1c6e-4050-b3d8-a1d87a361f1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">New Onset or Worsening Renal Impairment</content>
                        </paragraph>
                        <paragraph>Advise patients to avoid taking DESCOVY with concurrent or recent use of nephrotoxic agents. Renal impairment, including cases of acute renal failure, has been reported in association with the use of tenofovir prodrugs <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="62a2945d-ed53-48b2-ad6e-f7f56a7dc5c6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Decrease in Bone Mineral Density </content>
                        </paragraph>
                        <paragraph>Advise patients that decreases in bone mineral density have been observed with the use of DESCOVY. Assessment of bone mineral density (BMD) should be considered in patients who have a history of pathologic bone fracture or other risk factors for osteoporosis or bone loss <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b92fddd2-5e77-4357-82ed-b439867a9e74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Dosage </content>
                        </paragraph>
                        <paragraph>Inform patients that it is important to take DESCOVY on a regular dosing schedule with or without food and to avoid missing doses as it can result in development of resistance <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7eaf2f3d-7d18-4d68-99cf-6aa1b0f95141"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Registry </content>
                        </paragraph>
                        <paragraph>Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant women exposed to DESCOVY<content styleCode="italics"> [see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5d625cca-6afd-46f7-b516-606afb5444ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Instruct women with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in breast milk<content styleCode="italics"> [see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="25874cff-0ca3-4b8e-a4a0-42e10cecb79a"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>DESCOVY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.</paragraph>
                  <paragraph>© 2016 Gilead Sciences, Inc. All rights reserved.</paragraph>
               </text>
               <effectiveTime value="20160408"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2ee60437-a5e1-466b-8406-b6b4f49a2fba"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table styleCode="Noautorules">
                     <col align="left" valign="top" width="3%"/>
                     <col align="left" valign="top" width="37%"/>
                     <col align="left" valign="top" width="40%"/>
                     <col align="left" valign="top" width="20%"/>
                     <thead>
                        <tr>
                           <th align="center" colspan="4" styleCode="Botrule Lrule Rrule Toprule">Patient Information<br/>DESCOVY<sup>®</sup> (des-KOH-vee)<br/>(emtricitabine<br/>and tenofovir alafenamide)<br/>tablets</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="3">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="right" colspan="1">Issued 04/2016</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with DESCOVY.</content> For more information, see the section "<linkHtml href="#What">What should I tell my healthcare provider before taking DESCOVY?</linkHtml>"</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">Read this Patient Information before you start taking DESCOVY and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.  </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <paragraph ID="Important">
                                 <content styleCode="bold">What is the most important information I should know about DESCOVY?</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">DESCOVY can cause serious side effects, including: </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list>
                                 <item>
                                    <caption styleCode="bold">1.</caption>
                                    <content styleCode="bold">Build-up of lactic acid in your blood (lactic acidosis). </content>Lactic acidosis may happen in some people who take DESCOVY or similar medicines (nucleoside analogs). Lactic acidosis is a serious medical emergency that can lead to death. <br/>Lactic acidosis can be hard to identify early, because the symptoms could seem like symptoms of other health problems. <content styleCode="bold">Call your healthcare provider right away if you get any of the following symptoms which could be signs of lactic acidosis:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>feel very weak or tired </item>
                                 <item>have unusual (not normal) muscle pain</item>
                                 <item>have trouble breathing</item>
                                 <item>have stomach pain with nausea or vomiting</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list>
                                 <item>feel cold, especially in your arms and legs</item>
                                 <item>feel dizzy or lightheaded</item>
                                 <item>have a fast or irregular heartbeat</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list>
                                 <item>
                                    <caption styleCode="bold">2.</caption>
                                    <content styleCode="bold">Severe liver problems. </content>Severe liver problems may happen in people who take DESCOVY. In some cases, these liver problems can lead to death. Your liver may become large (hepatomegaly) and you may develop fat in your liver (steatosis). <br/>
                                    <content styleCode="bold">Call your healthcare provider right away if you get any of the following symptoms of liver problems</content>:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>your skin or the white part of your eyes turns yellow (jaundice)  </item>
                                 <item>dark "tea-colored" urine </item>
                                 <item>light-colored bowel movements (stools) </item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list>
                                 <item>nausea</item>
                                 <item>pain, aching, or tenderness on the right side of your stomach area</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="3" styleCode="Rrule">
                              <content styleCode="bold">You may be more likely to get lactic acidosis or severe liver problems if you are female, very overweight (obese), or have been taking DESCOVY or a similar medicine containing a nucleoside analog for a long time. </content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list>
                                 <item>
                                    <caption styleCode="bold">3.</caption>
                                    <content styleCode="bold">Worsening of Hepatitis B virus infection. DESCOVY is not for use to treat chronic hepatitis B virus (HBV) infection. If you have hepatitis B virus (HBV) infection and take DESCOVY, your HBV may get worse (flare-up) if you stop taking DESCOVY. A "flare-up" is when your HBV infection suddenly returns in a worse way than before.</content>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Do not run out of DESCOVY. Refill your prescription or talk to your healthcare provider before your DESCOVY is all gone.</item>
                                       <item>Do not stop taking DESCOVY without first talking to your healthcare provider.  </item>
                                       <item>If you stop taking DESCOVY, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking DESCOVY.</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">For more information about side effects, see the section "<linkHtml href="#Side">What are the possible side effects of DESCOVY?</linkHtml>" </content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is DESCOVY? </content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">DESCOVY is a prescription medicine that is used together with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in people 12 years of age and older.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome). </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">DESCOVY is <content styleCode="bold">not</content> for use to help reduce the risk of getting HIV-1 infection by sexual contact in adults at high risk.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">DESCOVY contains the prescription medicines emtricitabine (EMTRIVA<sup>®</sup>) and tenofovir alafenamide.  </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">It is not known if DESCOVY is safe and effective in children under 12 years of age or who weigh less than 77 lb.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">DESCOVY when used together with other HIV-1 medicines to treat HIV-1 infection may help:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Reduce the amount of HIV-1 in your blood. This is called "viral load".</item>
                                 <item>Increase the number of CD4+ (T) cells in your blood that help fight off other infections.  </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in your blood may help improve your immune system. This may reduce your risk of death or getting infections that can happen when your immune system is weak (opportunistic infections).</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">DESCOVY does not cure HIV-1 infections or AIDS.</content> You must keep taking HIV-1 medicines to control HIV-1 infection and decrease HIV-related illnesses.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Avoid doing things that can spread HIV-1 infection to others. </content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not share or re-use needles or other injection equipment. </item>
                                 <item>Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades. </item>
                                 <item>Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">Ask your healthcare provider if you have any questions about how to prevent passing HIV-1 to other people.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <paragraph ID="What">
                                 <content styleCode="bold">What should I tell my healthcare provider before taking DESCOVY?</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking DESCOVY, tell your healthcare provider if you:</content>
                              <list listType="unordered">
                                 <item>have liver problems, including hepatitis B virus infection</item>
                                 <item>have kidney problems</item>
                                 <item>have bone problems</item>
                                 <item>have any other medical conditions</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if DESCOVY can harm your unborn baby. Tell your healthcare provider if you become pregnant while taking DESCOVY.<br/>
                                    <content styleCode="bold">Pregnancy Registry:</content> There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry. 									 									</item>
                                 <item>are breastfeeding or plan to breastfeed. Do not breastfeed if you take DESCOVY. <list listType="unordered" styleCode="Disc">
                                       <item>You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.</item>
                                       <item>At least one of the medicines in DESCOVY can pass to your baby in your breast milk. It is not known if the other medicine in DESCOVY can pass into your breast milk. </item>
                                    </list>									Talk with your healthcare provider about the best way to feed your baby.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">Some medicines may interact with DESCOVY. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. 									<list listType="unordered" styleCode="Disc">
                                 <item>You can ask your healthcare provider or pharmacist for a list of medicines that interact with DESCOVY.</item>
                                 <item>
                                    <content styleCode="bold">Do not start a new medicine without telling your healthcare provider.</content> Your healthcare provider can tell you if it is safe to take DESCOVY with other medicines.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take DESCOVY?</content>
                              <list listType="unordered">
                                 <item>Take DESCOVY exactly as your healthcare provider tells you to take it. DESCOVY must be taken together with other HIV-1 medicines to treat HIV-1 infection. </item>
                                 <item>Take DESCOVY 1 time each day with or without food. </item>
                                 <item>Do not change your dose or stop taking DESCOVY without first talking with your healthcare provider. Stay under a healthcare provider's care when taking DESCOVY.</item>
                                 <item>Do not miss a dose of DESCOVY.</item>
                                 <item>If you take too much DESCOVY, call your healthcare provider or go to the nearest hospital emergency room right away.  </item>
                                 <item>When your DESCOVY supply starts to run low, get more from your healthcare provider or pharmacy.  This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to DESCOVY and become harder to treat.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <paragraph ID="Side">
                                 <content styleCode="bold">What are the possible side effects of DESCOVY?</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">DESCOVY may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">See "<linkHtml href="#Important">What is the most important information I should know about DESCOVY?</linkHtml>"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Changes in body fat can happen in people who take HIV-1 medicine. </content>These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms and face may also happen. The exact cause and long-term health effects of these conditions are not known. </item>
                                 <item>
                                    <content styleCode="bold">Changes in your immune system (Immune Reconstitution Syndrome)  </content>can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine.</item>
                                 <item>
                                    <content styleCode="bold">New or worse kidney problems, including kidney failure.  </content>Your healthcare provider should do blood and urine tests to check your kidneys before you start and while you are taking DESCOVY. Your healthcare provider may tell you to stop taking DESCOVY if you develop new or worse kidney problems.</item>
                                 <item>
                                    <content styleCode="bold">Bone problems </content>can happen in some people who take DESCOVY. Bone problems may include bone pain, softening or thinning (which may lead to fractures). Your healthcare provider may need to do tests to check your bones.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">The most common side effect of DESCOVY is nausea.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">These are not all the possible side effects of DESCOVY. For more information, ask your healthcare provider or pharmacist.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store DESCOVY?</content>
                              <list listType="unordered">
                                 <item>Store DESCOVY below 86 °F (30 °C).</item>
                                 <item>Keep DESCOVY in its original container. </item>
                                 <item>Keep the container tightly closed.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Keep DESCOVY and all medicines out of reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of DESCOVY.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use DESCOVY for a condition for which it was not prescribed. Do not give  DESCOVY to other people, even if they have the same symptoms you have. It may harm them.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about DESCOVY that is written for health professionals.  </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">For more information, call 1-800-445-3235 or go to www.DESCOVY.com.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in DESCOVY?</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Active ingredients:  </content>emtricitabine and tenofovir alafenamide.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Inactive ingredients: </content>croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">DESCOVY is a trademark of Gilead Sciences, Inc., or its related companies.  All other trademarks referenced herein are the property of their respective owners.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">© 2016 Gilead Sciences, Inc. All rights reserved.<br/>208215-GS-000</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20160408"/>
            </section>
         </component>
         <component>
            <section>
               <id root="dfb98ec4-db17-4a44-9ebf-7ecb8708ac36"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg/25 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 61958-<content styleCode="bold">2002</content>-1<br/>30 tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">Descovy<sup>®</sup>
                        <br/>(emtricitabine and tenofovir<br/>						alafenamide) Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg/25 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Note to pharmacist: Do not cover ALERT box with pharmacy label.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ALERT: Find out about medicines that<br/>should NOT be taken with Discovy<sup>®</sup>
                     </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20160408"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg/25 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="descovy-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>